Last reviewed · How we verify

BNT162b2 (Omi XBB.1.5) (bnt162b2-omi-xbb-1-5)

Pfizer · FDA-approved active Vaccine Quality 40/100

Pfizer's BNT162b2 (Omi XBB.1.5) is a marketed COVID-19 vaccine for individuals 6 months and older. It is a mRNA-based vaccine developed by Pfizer Inc. The vaccine is used to prevent COVID-19 in various age groups and individuals with certain medical conditions. BNT162b2 has generated significant revenue of $36.8B. The vaccine's mechanism involves the use of mRNA to instruct cells to produce a specific protein, triggering an immune response. This approach allows for rapid development and production of the vaccine. BNT162b2 has become a crucial tool in the fight against COVID-19.

At a glance

Generic namebnt162b2-omi-xbb-1-5
SponsorPfizer
Drug classmRNA vaccine
TargetSARS-CoV-2 spike protein
ModalityVaccine
Therapeutic areaImmunology
PhaseFDA-approved

Approved indications

Common side effects

No common side effects on file.

Drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: